成都奥达生物科技

Chengdu Auda Biotech is a clinical-stage biopharmaceutical company based in Chengdu, China, specializing in the development of long-acting peptide-based antiviral therapies. The company's core technology focuses on viral fusion inhibitors designed to treat chronic infectious diseases such as HIV and Hepatitis B, as well as emerging respiratory viruses like SARS-CoV-2. Its lead candidate, AD-101, is a next-generation HIV fusion inhibitor targeting the gp41 protein, aimed at providing a long-acting treatment option with a high barrier to resistance. Auda Biotech leverages its proprietary peptide engineering platform to optimize the half-life and potency of its drug candidates. The company is situated in the Chengdu Tianfu International Bio-Town and has received significant backing from regional venture capital and government-led investment funds.